Elevated HMGA2 expression is associated with cancer aggressiveness and predicts poor outcome in breast cancer

Jingjing Wu, Shizhen Zhang, Jinlan Shan, Zujian Hu, Xiyong Liu, Lirong Chen, Xingchang Ren, Lifang Yao, Hongqiang Sheng, Ling Li, David Ann, Yun Yen, Jian Wang, Xiaochen Wang

研究成果: 雜誌貢獻文章

32 引文 (Scopus)

摘要

High mobility group AT-hook 2 (HMGA2) is involved in a wide spectrum of biological processes and is upregulated in several tumors. Here, we collected 273 breast cancer (BC) specimens as a training set and 310 specimens as a validation set to examine the expression of HMGA2 by immunohistochemical staining. It was found that HMGA2 expression was significantly positively correlated with advanced tumor grade and poor survival. Subgroup analysis indicated that high level of HMGA2 was significantly correlated with poor prognosis, especially in the subgroups of stage II-III, low pathological grade and non-triple negative breast cancer cases. Gene set enrichment analysis (GSEA) demonstrated a significant positive correlation between HMGA2 level and the gene expression signature of metaplastic and mesenchymal phenotype. Importantly, we also observed that ectopic expression of HMGA2 promoted the migration and invasion of breast cancer cells, and protected cancer cells against genotoxic stress from agents stimulating P53 (Ser15) phosphorylation. As a conclusion, expression of HMGA2 might indicate more advanced malignancy of breast cancer. Thus we believe HMGA2 could serve as a biomarker of poor prognosis and a novel target in treating BC tumors.
原文英語
頁(從 - 到)284-292
頁數9
期刊Cancer Letters
376
發行號2
DOIs
出版狀態已發佈 - 七月 1 2016

指紋

AT-Hook Motifs
Breast Neoplasms
Neoplasms
Biological Phenomena
Transcriptome
DNA Damage
Biomarkers
Phosphorylation
Staining and Labeling

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

引用此文

Elevated HMGA2 expression is associated with cancer aggressiveness and predicts poor outcome in breast cancer. / Wu, Jingjing; Zhang, Shizhen; Shan, Jinlan; Hu, Zujian; Liu, Xiyong; Chen, Lirong; Ren, Xingchang; Yao, Lifang; Sheng, Hongqiang; Li, Ling; Ann, David; Yen, Yun; Wang, Jian; Wang, Xiaochen.

於: Cancer Letters, 卷 376, 編號 2, 01.07.2016, p. 284-292.

研究成果: 雜誌貢獻文章

Wu, J, Zhang, S, Shan, J, Hu, Z, Liu, X, Chen, L, Ren, X, Yao, L, Sheng, H, Li, L, Ann, D, Yen, Y, Wang, J & Wang, X 2016, 'Elevated HMGA2 expression is associated with cancer aggressiveness and predicts poor outcome in breast cancer', Cancer Letters, 卷 376, 編號 2, 頁 284-292. https://doi.org/10.1016/j.canlet.2016.04.005
Wu, Jingjing ; Zhang, Shizhen ; Shan, Jinlan ; Hu, Zujian ; Liu, Xiyong ; Chen, Lirong ; Ren, Xingchang ; Yao, Lifang ; Sheng, Hongqiang ; Li, Ling ; Ann, David ; Yen, Yun ; Wang, Jian ; Wang, Xiaochen. / Elevated HMGA2 expression is associated with cancer aggressiveness and predicts poor outcome in breast cancer. 於: Cancer Letters. 2016 ; 卷 376, 編號 2. 頁 284-292.
@article{9b11b3191d6e489f8249332f89c31ada,
title = "Elevated HMGA2 expression is associated with cancer aggressiveness and predicts poor outcome in breast cancer",
abstract = "High mobility group AT-hook 2 (HMGA2) is involved in a wide spectrum of biological processes and is upregulated in several tumors. Here, we collected 273 breast cancer (BC) specimens as a training set and 310 specimens as a validation set to examine the expression of HMGA2 by immunohistochemical staining. It was found that HMGA2 expression was significantly positively correlated with advanced tumor grade and poor survival. Subgroup analysis indicated that high level of HMGA2 was significantly correlated with poor prognosis, especially in the subgroups of stage II-III, low pathological grade and non-triple negative breast cancer cases. Gene set enrichment analysis (GSEA) demonstrated a significant positive correlation between HMGA2 level and the gene expression signature of metaplastic and mesenchymal phenotype. Importantly, we also observed that ectopic expression of HMGA2 promoted the migration and invasion of breast cancer cells, and protected cancer cells against genotoxic stress from agents stimulating P53 (Ser15) phosphorylation. As a conclusion, expression of HMGA2 might indicate more advanced malignancy of breast cancer. Thus we believe HMGA2 could serve as a biomarker of poor prognosis and a novel target in treating BC tumors.",
keywords = "Breast cancer, High mobility group AT-hook 2, Prognostic biomarker, Tumor progression",
author = "Jingjing Wu and Shizhen Zhang and Jinlan Shan and Zujian Hu and Xiyong Liu and Lirong Chen and Xingchang Ren and Lifang Yao and Hongqiang Sheng and Ling Li and David Ann and Yun Yen and Jian Wang and Xiaochen Wang",
year = "2016",
month = "7",
day = "1",
doi = "10.1016/j.canlet.2016.04.005",
language = "English",
volume = "376",
pages = "284--292",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Elevated HMGA2 expression is associated with cancer aggressiveness and predicts poor outcome in breast cancer

AU - Wu, Jingjing

AU - Zhang, Shizhen

AU - Shan, Jinlan

AU - Hu, Zujian

AU - Liu, Xiyong

AU - Chen, Lirong

AU - Ren, Xingchang

AU - Yao, Lifang

AU - Sheng, Hongqiang

AU - Li, Ling

AU - Ann, David

AU - Yen, Yun

AU - Wang, Jian

AU - Wang, Xiaochen

PY - 2016/7/1

Y1 - 2016/7/1

N2 - High mobility group AT-hook 2 (HMGA2) is involved in a wide spectrum of biological processes and is upregulated in several tumors. Here, we collected 273 breast cancer (BC) specimens as a training set and 310 specimens as a validation set to examine the expression of HMGA2 by immunohistochemical staining. It was found that HMGA2 expression was significantly positively correlated with advanced tumor grade and poor survival. Subgroup analysis indicated that high level of HMGA2 was significantly correlated with poor prognosis, especially in the subgroups of stage II-III, low pathological grade and non-triple negative breast cancer cases. Gene set enrichment analysis (GSEA) demonstrated a significant positive correlation between HMGA2 level and the gene expression signature of metaplastic and mesenchymal phenotype. Importantly, we also observed that ectopic expression of HMGA2 promoted the migration and invasion of breast cancer cells, and protected cancer cells against genotoxic stress from agents stimulating P53 (Ser15) phosphorylation. As a conclusion, expression of HMGA2 might indicate more advanced malignancy of breast cancer. Thus we believe HMGA2 could serve as a biomarker of poor prognosis and a novel target in treating BC tumors.

AB - High mobility group AT-hook 2 (HMGA2) is involved in a wide spectrum of biological processes and is upregulated in several tumors. Here, we collected 273 breast cancer (BC) specimens as a training set and 310 specimens as a validation set to examine the expression of HMGA2 by immunohistochemical staining. It was found that HMGA2 expression was significantly positively correlated with advanced tumor grade and poor survival. Subgroup analysis indicated that high level of HMGA2 was significantly correlated with poor prognosis, especially in the subgroups of stage II-III, low pathological grade and non-triple negative breast cancer cases. Gene set enrichment analysis (GSEA) demonstrated a significant positive correlation between HMGA2 level and the gene expression signature of metaplastic and mesenchymal phenotype. Importantly, we also observed that ectopic expression of HMGA2 promoted the migration and invasion of breast cancer cells, and protected cancer cells against genotoxic stress from agents stimulating P53 (Ser15) phosphorylation. As a conclusion, expression of HMGA2 might indicate more advanced malignancy of breast cancer. Thus we believe HMGA2 could serve as a biomarker of poor prognosis and a novel target in treating BC tumors.

KW - Breast cancer

KW - High mobility group AT-hook 2

KW - Prognostic biomarker

KW - Tumor progression

UR - http://www.scopus.com/inward/record.url?scp=84963610832&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963610832&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2016.04.005

DO - 10.1016/j.canlet.2016.04.005

M3 - Article

VL - 376

SP - 284

EP - 292

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 2

ER -